Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Health and Quality of Life Outcomes
Published in: Health and Quality of Life Outcomes 1/2018

Open Access 01-12-2018 | Research

Review and critical appraisal of studies mapping from quality of life or clinical measures to EQ-5D: an online database and application of the MAPS statement

Authors: Helen Dakin, Lucy Abel, Richéal Burns, Yaling Yang

Published in: Health and Quality of Life Outcomes | Issue 1/2018

Login to get access

Abstract

Background

The Health Economics Research Centre (HERC) Database of Mapping Studies was established in 2013, based on a systematic review of studies developing mapping algorithms predicting EQ-5D. The Mapping onto Preference-based measures reporting Standards (MAPS) statement was published in 2015 to improve reporting of mapping studies. We aimed to update the systematic review and assess the extent to which recently-published studies mapping condition-specific quality of life or clinical measures to the EQ-5D follow the guidelines published in the MAPS Reporting Statement.

Methods

A published systematic review was updated using the original inclusion criteria to include studies published by December 2016. We included studies reporting novel algorithms mapping from any clinical measure or patient-reported quality of life measure to either the EQ-5D-3L or EQ-5D-5L. Titles and abstracts of all identified studies and the full text of papers published in 2016 were assessed against the MAPS checklist.

Results

The systematic review identified 144 mapping studies reporting 190 algorithms mapping from 110 different source instruments to EQ-5D. Of the 17 studies published in 2016, nine (53%) had titles that followed the MAPS statement guidance, although only two (12%) had abstracts that fully addressed all MAPS items. When the full text of these papers was assessed against the complete MAPS checklist, only two studies (12%) were found to fulfil or partly fulfil all criteria. Of the 141 papers (across all years) that included abstracts, the items on the MAPS statement checklist that were fulfilled by the largest number of studies comprised having a structured abstract (95%) and describing target instruments (91%) and source instruments (88%).

Conclusions

The number of published mapping studies continues to increase. Our updated database provides a convenient way to identify mapping studies for use in cost-utility analysis. Most recent studies do not fully address all items on the MAPS checklist.
Appendix
Available only for authorised users
Literature
1.
2.
Longworth L, Rowen D. Mapping to obtain EQ-5D utility values for use in NICE health technology assessments. Value Health. 2013;16:202–10.CrossRefPubMed
3.
4.
Brazier JE, Yang Y, Tsuchiya A, Rowen DL. A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ. 2010;11:215–25.CrossRefPubMed
5.
Mortimer D, Segal L, Sturm J. Can we derive an ‘exchange rate’ between descriptive and preference-based outcome measures for stroke? Results from the transfer to utility (TTU) technique. Health Qual Life Outcomes. 2009;7:33.CrossRefPubMedPubMedCentral
6.
Stein K, Fry A, Round A, Milne R, Brazier J. What value health?: a review of health state values used in early technology assessments for NICE. Appl Health Econ Health Policy. 2005;4:219–28.CrossRefPubMed
7.
Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, Bonsel G, Badia X. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20:1727–36.CrossRefPubMedPubMedCentral
8.
Devlin N, Shah K, Feng Y, Mulhern B, van Hout B: Valuing health-related quality of life: an EQ-5D-5L value set for England. Office of Health Economics Research Paper 2016, 16/01.
9.
Petrou S, Rivero-Arias O, Dakin H, Longworth L, Oppe M, Froud R, Gray A. The MAPS reporting statement for studies mapping onto generic preference-based outcome measures: explanation and elaboration. PharmacoEconomics. 2015;33:993–1011.CrossRefPubMed
10.
Mortimer D, Segal L. Comparing the incomparable? A systematic review of competing techniques for converting descriptive measures of health status into QALY-weights. Med Decis Mak. 2008;28:66–89.CrossRef
11.
Round J. Capturing information loss in estimates of uncertainty that arise from mapping algorithms. Aberdeen: Presented at the Health Economics Study Group (HESG) meeting, Summer 2008; 2008.
12.
Lin FJ, Longworth L, Pickard AS. Evaluation of content on EQ-5D as compared to disease-specific utility measures. Qual Life Res. 2013;22:853–74.CrossRefPubMed
13.
Cheung YB, Luo N, Ng R, Lee CF. Mapping the functional assessment of cancer therapy-breast (FACT-B) to the 5-level EuroQoL Group’s 5-dimension questionnaire (EQ-5D-5L) utility index in a multi-ethnic Asian population. Health Qual Life Outcomes. 2014;12:180.CrossRefPubMedPubMedCentral
14.
Richardson J, Iezzi A, Khan MA, Maxwell A. Validity and reliability of the Assessment of Quality of Life (AQoL)-8D multi-attribute utility instrument. Patient. 2014;7:85–96.CrossRefPubMed
15.
Kaambwa B, Chen G, Ratcliffe J, Iezzi A, Maxwell A, Richardson J. Mapping between the Sydney Asthma Quality of Life Questionnaire (AQLQ-S) and five multi-attribute utility instruments (MAUIs). PharmacoEconomics. 2017;35:111–24.CrossRefPubMed
16.
Gamst-Klaussen T, Chen G, Lamu AN, Olsen JA. Health state utility instruments compared: inquiring into nonlinearity across EQ-5D-5L, SF-6D, HUI-3 and 15D. Qual Life Res. 2016;25:1667–78.CrossRefPubMed
17.
18.
Khan I, Morris S, Pashayan N, Matata B, Bashir Z, Maguirre J. Comparing the mapping between EQ-5D-5L, EQ-5D-3L and the EORTC-QLQ-C30 in non-small cell lung cancer patients. Health Qual Life Outcomes. 2016;14:60.CrossRefPubMedPubMedCentral
19.
van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, Lloyd A, Scalone L, Kind P, Pickard AS. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15:708–15.CrossRefPubMed
20.
Hernández Alava M, Wailoo AJ, Ara R. Tails from the peak district: adjusted limited dependent variable mixture models of EQ-5D questionnaire health state utility values. Value Health. 2012;15:550–61.CrossRefPubMed
21.
Chen G, McKie J, Khan MA, Richardson JR. Deriving health utilities from the MacNew Heart Disease Quality of Life Questionnaire. Eur J Cardiovasc Nurs. 2015;14:405–15.CrossRefPubMed
22.
Grochtdreis T, Brettschneider C, Hajek A, Schierz K, Hoyer J, Koenig H-H. Mapping the Beck depression inventory to the EQ-5D-3L in patients with depressive disorders. J Ment Health Policy Econ. 2016;19:79–89.PubMed
23.
Chen G, Khan MA, Iezzi A, Ratcliffe J, Richardson J. Mapping between 6 multiattribute utility instruments. Med Decis Mak. 2016;36:160–75.CrossRef
24.
Khan I, Morris S. A non-linear beta-binomial regression model for mapping EORTC QLQ- C30 to the EQ-5D-3L in lung cancer patients: a comparison with existing approaches. Health Qual Life Outcomes. 2014;12:163.CrossRefPubMedPubMedCentral
25.
Kent S, Gray A, Schlackow I, Jenkinson C, McIntosh E. Mapping from the Parkinson’s disease questionnaire PDQ-39 to the generic EuroQol EQ-5D-3L: the value of mixture models. Med Decis Mak. 2015;35:902–11.CrossRef
26.
Khan KA, Madan J, Petrou S, Lamb SE. Mapping between the Roland Morris Questionnaire and generic preference-based measures. Value Health. 2014;17:686–95.CrossRefPubMed
27.
Chavez LJ, Bradley K, Tefft N, Liu CF, Hebert P, Devine B. Preference weights for the spectrum of alcohol use in the U.S. population. Drug Alcohol Depend. 2016;161:206–13.CrossRefPubMed
28.
Dixon P, Dakin H, Wordsworth S. Generic and disease-specific estimates of quality of life in macular degeneration: mapping the MacDQoL onto the EQ-5D-3L. Qual Life Res. 2016;25:935–45.CrossRefPubMed
29.
Hatswell AJ, Vegter S. Measuring quality of life in opioid-induced constipation: mapping EQ-5D-3L and PAC-QOL. Heal Econ Rev. 2016;6:14.
30.
Hoyle CK, Tabberer M, Brooks J. Mapping the COPD assessment test onto EQ-5D. Value Health. 2016;19:469–77.CrossRefPubMed
31.
Kim HL, Kim D, Jang EJ, Lee MY, Song HJ, Park SY, Cho SK, Sung YK, Choi CB, Won S, et al. Mapping health assessment questionnaire disability index (HAQ-DI) score, pain visual analog scale (VAS), and disease activity score in 28 joints (DAS28) onto the EuroQol-5D (EQ-5D) utility score with the KORean Observational study Network for Arthritis (KORONA) registry data. Rheumatol Int. 2016;36:505–13.CrossRefPubMed
32.
Lindkvist M, Feldman I. Assessing outcomes for cost-utility analysis in mental health interventions: mapping mental health specific outcome measure GHQ-12 onto EQ-5D-3L. Health Qual Life Outcomes. 2016;14:134.CrossRefPubMedPubMedCentral
33.
Marriott E-R, van Hazel G, Gibbs P, Hatswell AJ. Mapping EORTC-QLQ-C30 to EQ-5D-3L in patients with colorectal cancer. J Med Econ. 2016;20:193–9.CrossRefPubMed
34.
Mlcoch T, Sedova L, Stolfa J, Urbanova M, Suchy D, Smrzova A, Jircikova J, Pavelka K, Dolezal T. Mapping the relationship between clinical and quality-of-life outcomes in patients with ankylosing spondylitis. Expert Rev Pharmacoecon Outcomes Res. 2017;17:203–11.CrossRefPubMed
35.
Nair SC, Welsing PM, Marijnissen AK, Sijtsma P, Bijlsma JW, van Laar JM, Lafeber FP, de Wit GA. Does disease activity add to functional disability in estimation of utility for rheumatoid arthritis patients on biologic treatment? Rheumatology (Oxford). 2016;55:94–102.CrossRef
36.
Ruiz MA, Gutierrez LL, Monroy M, Rejas J. Mapping of the OAB-SF questionnaire onto EQ-5D in Spanish patients with overactive bladder. Clin Drug Investig. 2016;36:267–79.CrossRefPubMed
37.
Siani C, de Peretti C, Millier A, Boyer L, Toumi M. Predictive models to estimate utility from clinical questionnaires in schizophrenia: findings from EuroSC. Qual Life Res. 2016;25:925–34.CrossRefPubMed
38.
Wailoo AJ, Hernandez-Alava M, Manca A, Mejia A, Ray J, Crawford B, Botteman M, Busschbach J. Mapping to estimate health-state utility from non–preference-based outcome measures: an ISPOR good practices for outcomes research task force report. Value Health. 2017;20:18–27.CrossRefPubMed
Metadata
Title
Review and critical appraisal of studies mapping from quality of life or clinical measures to EQ-5D: an online database and application of the MAPS statement
Authors
Helen Dakin
Lucy Abel
Richéal Burns
Yaling Yang
Publication date
01-12-2018
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2018
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/s12955-018-0857-3

Other articles of this Issue 1/2018

Health and Quality of Life Outcomes 1/2018 Go to the issue

Research

Responsiveness of the Short Warwick Edinburgh Mental Well-Being Scale (SWEMWBS): evaluation a clinical sample

Research

The relationship between quality of life and physical fitness in people with severe mental illness

Research

Quality of life among caregivers of sickle cell disease patients: a cross sectional study

Research

Development and evaluation of a measure of patient-reported symptoms of Blepharitis

Research

The interpretation of change score of the pain disability index after vocational rehabilitation is baseline dependent

Research

Comparing the effects of China’s three basic health insurance schemes on the equity of health-related quality of life: using the method of coarsened exact matching